---
title: 'Vice President, Clinical Development at 4D Molecular Therapeutics'
canonical: 'https://feeny.ai/job/vice-president-clinical-development-4d-molecular-therapeutics-united-states-8zdnvfs5n4ha'
type: 'job'
last_seen: '2026-09-13'
---

# Vice President, Clinical Development at 4D Molecular Therapeutics

- **Company:** 4D Molecular Therapeutics
- **Location:** United States
- **Work type:** remote
- **Posted:** 2026-08-06
- **Last confirmed live:** 2026-09-13
- **Apply:** https://4dmoleculartherapeutics.com/careers/?gh_jid=4722065005

## Job description

Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery

## GENERAL SUMMARY

Reporting to the Chief Medical Officer, the VP Clinical Development, Ophthalmology provides strategic and operational leadership for the global development of ophthalmic genetic medicines in Drug Development.

We seek an experienced physician to play a critical role at 4DMT as we spearhead the introduction of intravitreally delivered genetic medicines for the treatment of the most common causes of irreversible blindness. The VP, Clinical Development will be a primary point person for medical oversight of clinical studies, with responsibilities including medical monitoring, review and interpretation of clinical trial data, clinical trial design, protocol development, and drafting of key clinical documents such as protocols, CSRs, briefing packages, INDs, NDAs, BLAs, MAAs, and other regulatory documents. This role will be responsible for timely execution of deliverables in close collaboration with relevant internal and external partners.

## RESPONSIBILITIES:

- Serve as the primary medical monitor for multiple ophthalmology clinical trials, providing expert oversight of patient safety, data integrity, and protocol adherence throughout study execution.
- Direct and mentor a team of medical monitors, ensuring high standards of medical oversight and data review, while maintaining accountability for real-time monitoring activities and timely delivery of critical clinical trial outputs.
- Provide medical leadership for cross-functional internal workstreams including pharmacovigilance, biostatistics, clinical operations, regulatory affairs, etc.
- Provide oversight and lead teams responsible for development plans, study protocols, amendments, ICFs, IBs, INDs, annual reports, CSRs, regulatory response documents, and other regulatory submissions or documents as appropriate.
- Collaborate closely with Clinical Operations and be accountable for clinical trial conduct and timelines for associated key deliverables.
- Keep up to date with compliance, SOPs and adhere to ICH, GCP, and relevant regulatory guidelines.
- Provide medical leadership for internal audits and regulatory inspections.
- Assist in preparation of materials for Advisory Board meetings, BOD meetings, etc
- Represent 4DMT and lead interactions and collaborations with potential partners.
- Represent the Ophthalmology Therapeutic Area with key external stakeholders, including patients and patient advocacy groups, external experts, investors, and the ophthalmic and biotech business communities
- Travel domestically and internationally as required, approximately 20%. Other duties as assigned; nothing in this job description restricts management’s right to assign or reassign duties and responsibilities to this job at any time.

## QUALIFICATIONS:

Education:

- MD Degree
- Clinical training in Ophthalmology preferred
- Retina fellowship training a plus
- Board Certification (or equivalent) preferred

Experience:

- Minimum of 8 years of biopharma industry experience in drug development.
- Phase 3 ophthalmology experience; retinal disease highly preferred.
- Experience with NDA, BLA or MAA submission(s). Drug approval(s) a plus.
- Experience with gene therapy, other areas of Drug Development and commercialization is a plus.

Skills:

- Strong interpersonal skills and high emotional coefficient
- Highly effective written and verbal communication skills
- Excellent analytical, problem-solving and strategic planning skills.
- Up to date understanding of the ophthalmic competitive landscape with a focus on retina
- Prior clinical trial experience in retina highly preferred.
- Ability to understand and translate complex data to key messages
- Ability to thrive in a fast-paced environment.
- Proven ability to prioritize effectively
- Proven ability to plan and conduct clinical trials ensuring high-quality trial execution and results within established timelines; demonstrated track record working effectively in cross-functional teams and workstreams including pharmacovigilance, biostatistics, clinical operations, and regulatory affairs.
- Experience in successfully presenting and interacting with the Ophthalmic Retina Community and regulatory authorities in US, EU and APAC
- Integrated understanding of FDA, EMA, ICH, and GCP guidelines. Prior interactions with FDA and EMA regulatory agencies is desirable.
- Track record of thinking strategically and executing to strategy
- Demonstrated success in influencing colleagues and senior leaders in various departments.
- Experience building and leading teams and driving engagement in a matrixed environment.
- Attention to detail, internal drive to generate high-quality work, and sense of passion and urgency to achieve team and program goals.
- Track record of developing talent
- Demonstrates high integrity.

Physical Requirements and Working Conditions:

- Physical Activity - Repetitive motions: Making substantial movements (motions) of the wrists, hands, and/or fingers. Fingering: Picking, pinching, typing or otherwise working, primarily with fingers rather than with whole hand or arm as in handling. Talking: Expressing or exchanging ideas by means of the spoken word.
- Physical Requirements - Sedentary work: Exerting up to 10 pounds of force occasionally and/or a negligible amount of force frequently or constantly to lift, carry, push, pull or otherwise move objects, including the human body. Sedentary work involves sitting most of the time. Jobs are sedentary if walking and standing are required only occasionally and all other sedentary criteria are met.
- Working Conditions - The worker is not substantially exposed to adverse environmental conditions (as in typical office or administrative work).

Base salary compensation range: $350,000 - $430,000

Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.

4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.

Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities

## About 4D Molecular Therapeutics

## Company Overview
- **One-liner**: 4D Molecular Therapeutics is a late-stage clinical biotechnology company inventing and developing customized genetic medicines using a proprietary vector evolution platform to treat large-market diseases.
- **Entity Type**: Public (NASDAQ: FDMT)
- **Headquarters**: Emeryville, California, United States
- **Founded**: 2013
- **Founders**: David Kirn, MD (Co-Founder, President, and CEO)

## Core Business
- **Primary industry**: Biotechnology / Genetic Medicine / Gene Therapy
- **Target customers**: B2B (partnerships with other biopharma companies) and B2C (patients with retinal and pulmonary diseases)
- **Mission or purpose statement**: "To unlock the full potential of genetic medicines for large market diseases" by harnessing directed evolution to invent customized and enhanced vectors for transformative products.

## Products & Services
- **4D-150**: A clinical-stage genetic medicine candidate for retinal vascular diseases (wet age-related macular degeneration and diabetic macular edema). It is designed as a single, routine, low-dose intravitreal injection that provides multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C). Currently in Phase 3 clinical trials (4FRONT-1 and 4FRONT-2) for wet AMD and Phase 1/2 for DME.
- **4D-710**: An investigational genetic medicine candidate for cystic fibrosis lung disease. It uses the A101 vector for aerosol delivery of a corrective CFTR transgene (CFTR∆R) and is designed for patients ineligible for or who have discontinued CFTR modulator therapy. Currently in Phase 1/2.
- **4D-175**: A preclinical candidate for geographic atrophy (a form of dry AMD) using the R100 vector to deliver a shortened form of human complement factor H (sCFH) to restore normal complement regulation.
- **4D-725**: A preclinical candidate for alpha-1 antitrypsin (A1AT) lung disease using the A101 vector for aerosol delivery.

## Market Standing
- **Valuation/Market Cap**: $756.4 million (as of latest data from LinkedIn)
- **Key Metric**: Annual Revenue of $85.2 million (as of latest data from LinkedIn)
- **Notable Investors/Partners**: The company is publicly traded (IPO in 2020). Key partnerships are sought for pipeline candidates like 4D-175 and 4D-725.
- **Growth Signals**: The company is a late-stage biotech with two Phase 3 trials (4FRONT-1 and 4FRONT-2) for its lead candidate 4D-150 in wet AMD, and a Phase 1/2 trial for 4D-710 in cystic fibrosis. The company has a presence in Ecuador, France, and India. LinkedIn followers grew 24.7% year-over-year.

## Competitive Advantages
- **Proprietary Vector Platform (Therapeutic Vector Evolution)**: The company uses directed evolution to create customized and proprietary AAV vectors (e.g., R100 for retina, A101 for lung) that are optimized for specific tissues and routes of administration, which is a significant differentiator from standard gene therapy approaches.
- **Large-Market Focus**: Unlike many gene therapy companies targeting ultra-rare diseases, 4DMT is focused on large-market indications (wet AMD, DME, cystic fibrosis) with high unmet need, offering a potentially massive commercial opportunity.
- **Durable, Single-Dose Therapies**: Their products are designed to provide multi-year efficacy from a single injection, which could dramatically reduce treatment burden for patients compared to current standard-of-care (e.g., frequent eye injections for wet AMD).

## Strategic Focus
- **Advancing Late-Stage Pipeline**: The primary focus is executing the Phase 3 programs for 4D-150 in wet AMD and progressing 4D-710 in cystic fibrosis.
- **Expanding Indications**: The company is exploring 4D-150 for diabetic macular edema (DME) and seeking partnerships to advance 4D-175 (geographic atrophy) and 4D-725 (A1AT deficiency).
- **Platform Expansion**: Continuing to leverage the Therapeutic Vector Evolution platform to develop new genetic medicines for other large-market diseases.

## Why Work Here
- **Mission-Driven Culture**: The company is deeply committed to "daring to cure" and unlocking the potential of genetic medicine for patients with devastating diseases. Core values include "Dare to Cure," "Break Boundaries," "Prepare & Execute Relentlessly," and "Beyond Yourself."
- **Innovative Science**: Employees work on cutting-edge science at the intersection of gene therapy, vector engineering, and clinical development, tackling some of the biggest challenges in medicine.
- **Collaborative Environment**: The company emphasizes teamwork, internal and external collaboration, and a culture that empowers innovation.
- **Location & Perks**: Based in Emeryville, CA (San Francisco Bay Area). The company offers a competitive benefits package and a dynamic, collaborative environment.
- **Diversity & Inclusion**: 4DMT champions diversity, equity, and inclusion through an employee-led initiative called "4Diversity," which partners with charitable organizations and focuses on social equity.
- **Work Authorization**: Candidates must be authorized to work in the U.S. The company does not sponsor new nonimmigrant visa status petitions but welcomes candidates who require transfers or extensions.

## Sources
1. [4dmoleculartherapeutics.com](https://4dmoleculartherapeutics.com/)
2. [4dmoleculartherapeutics.com - About](https://4dmoleculartherapeutics.com/about/)
3. [4dmoleculartherapeutics.com - Careers](https://4dmoleculartherapeutics.com/careers/)
4. [4dmoleculartherapeutics.com - Pipeline](https://4dmoleculartherapeutics.com/pipeline/)
5. [LinkedIn - 4D Molecular Therapeutics](https://www.linkedin.com/company/4d-molecular-therapeutics-llc)

## Other roles at 4D Molecular Therapeutics

- [Clinical Trial Manager (Contract)](https://feeny.ai/job/clinical-trial-manager-contract-4d-molecular-therapeutics-emeryville-z7y6de7nnaew) — Emeryville, CA / United States
- [In-House Clinical Research Associate (Contract)](https://feeny.ai/job/in-house-clinical-research-associate-contract-4d-molecular-therapeutics-united-nvv6yy4zr7sd) — United States
- [Research Associate, Formulation Development (Contract)](https://feeny.ai/job/research-associate-formulation-development-contract-4d-molecular-therapeutics-pfa7f1vctz9z) — Emeryville, CA
- [Senior Director, Clinical Quality  Assurance (CQA)](https://feeny.ai/job/senior-director-clinical-quality-assurance-cqa-4d-molecular-therapeutics-united-xhe4n9jrfe00) — United States
- [Associate Director, Clinical Operations](https://feeny.ai/job/associate-director-clinical-operations-4d-molecular-therapeutics-united-states-sdf0e2rc2tda) — United States
- [Sr. QA Computer System Validation Mgr.](https://feeny.ai/job/sr-qa-computer-system-validation-mgr-4d-molecular-therapeutics-united-states-aq7bmg1j30ra) — United States
- [Director, Corporate Counsel](https://feeny.ai/job/director-corporate-counsel-4d-molecular-therapeutics-united-states-tqb6yhgnqdae) — United States
- [Senior Director, IT Compliance & Governance (Contract)](https://feeny.ai/job/senior-director-it-compliance-governance-contract-4d-molecular-therapeutics-p4334wpdrvzd) — United States
- [Senior Business Systems Architect](https://feeny.ai/job/senior-business-systems-architect-4d-molecular-therapeutics-united-states-0jycx224r9tk) — United States
- [Executive Medical Director (Retina Program)](https://feeny.ai/job/executive-medical-director-retina-program-4d-molecular-therapeutics-united-kr1mkby7m4kt) — United States